1Chen HJ, Bloch KJ, Maclean JA. Acute eosinophilic hep atitis from trovafloxacin [J]. N Engl J Med, 2000, 342(5): 359.
2Stahlmann R, Schwabe R. Safety profile of grepafloxi cin as compared with other fluoquinolones [J]. J Antimicrob Chemther, 1997, 50(suppl): 83.
3Lode H, Garau J, Grassi C, et al. Treatment of community-acquired pneumonia: a randomised comparision of sparfloxicin amoxicillin-clavulanic acid and erthromycn[J]. Eur Resp J, 1995, 8: 1999.
4Henry D, Stein W, Bensch G, et al. Treatment of community-acquired peneumonia with sparfloxicin and ery thromycin[C]. Washington D C:American Society for Microbiology, 1996: 45.
5Springsklee M, Reiter C, Meyer J M. Safety and tolera bility profile of moxifloxacin [J]. Clin Microbiolb Infect, 1999, 36: 140.
6Vincent J, Agin M, Laboy-Goral, et al. Effect of dosing with food and bedtime dosing on the incidence of dizziness/lighteadedness with trovafloxacin in young, female subjects [J]. Antimicrob Agents Chemother, 1998, 42:24.
7Chodosh S, Lakshminarayan S, Swarz H, et al. Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligram
8Langan C E, Cranfield R, Breisch S, et al. Randomized doubleblind study of grepafloxicin versus amoxicillin in patients with acute bacterial exacerbations of chronic bronchitis [J]. J Antimicrob Chemther, 1998, 42:114.
9Rick D, Anthony M, Julia A.Ciprofloxacin an updated review of its pharmacology therapeutic efficacy and tolerability [J]. DRUGS, 1996, 51: 1024.
10Bowie W R, Willetts V, Jeweson P. Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone fleroxacin [J]. Antimicrob Agents Chemother, 1989, 33: 1778.
